Shares of NxStage Medical (NXTM) remain elevated since the dialysis system provider surprised Wall Street in November with a much narrower loss than expected. The company’s CEO Jeffrey Burbank said profitability is clearly within sight. 'We are right at the cusp of becoming profitable,' said Burbank. 'We’ve indicated that 2017 is probably the year for that, but if we do things really well then 2016 may be the year.' The Wall Street consensus estimate is for NxStage to lose 15 cents per share in 2016. Shares of NxStage surged over 22% last month after the company reported a third quarter loss of $1.7 million, or 3 cents per share, thoroughly beating the Wall Street consensus estimate of a loss of 8 cents per share. The medical device-maker posted revenue of $86.5 million in the period, which also topped the Street forecast of $82.1 million. NxStage is forecasting revenue in the range of $86 million to $87 million for the current quarter ending in December, and full-year revenue in the range of $332 million to $333 million.